Search Results - Brian G.M. Durie

Refine Results
  1. 1
    A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

    A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival by Brian G.M. Durie, Sydney E. Salmon

    Published 1975
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer

    Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer by Stephen E. Jones, Brian G.M. Durie, Sydney E. Salmon

    Published 1975
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials

    Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials by Brian G.M. Durie, Joth Jacobson, Bart Barlogie, John Crowley

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system

    C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system by Régis Bataille, Mario Boccadoro, Bernard Klein, BrianG.M. Durie, Alessandro Pileri

    Published 1992
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

    Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives by Sagar Lonial, Brian G.M. Durie, Antonio Palumbo, Jesús F. San Miguel

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment

    Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment by Heinz Ludwig, Susie Novis Durie, Angela Meckl, Axel Hinke, Brian G.M. Durie

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

    A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience by Joth Jacobson, Mohamad A. Hussein, Bart Barlogie, Brian G.M. Durie, John J. Crowley

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis by Jeffrey A. Zonder, Bart Barlogie, Brian G.M. Durie, Jason McCoy, John Crowley, Mohamad A. Hussein

    Published 2006
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  9. 9
    Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

    Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and Unive... by Bart Barlogie, Michel Attal, John Crowley, Frits van Rhee, Jackie Szymonifka, Philippe Moreau, Brian G.M. Durie, Jean‐Luc Harousseau

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods

    MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan Flores‐Montero, Qi Gao, Maesa Koeber, Jessica Wardrope, Brian G.M. Durie, Ahmet Doǧan, Alberto Órfão, Ola Landgren

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) by Jeffrey A. Zonder, John Crowley, Mohamad A. Hussein, Vanessa Bolejack, Dennis F. Moore, Brock Whittenberger, Muneer H. Abidi, Brian G.M. Durie, Bart Barlogie

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

    Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma by Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Eli Gabayan, Amitabha Mazumder, David P. Schenkein, John Crowley

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

    Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma by Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

    Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report by David Murray, Noemí Puig, Sigurður Y. Kristinsson, Saad Z. Usmani, Angela Dispenzieri, Giada Bianchi, Shaji Kumar, Wee Joo Chng, Roman Hájek, Bruno Paiva, Anders Waage, S. Vincent Rajkumar, Brian G.M. Durie

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

    Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cel... by Brian G.M. Durie, Antje Hoering, Muneer H. Abidi, S. Vincent Rajkumar, Joshua Epstein, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Rachael Sexton, Robert Z. Orlowski, Bart Barlogie, Angela Dispenzieri

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

    Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously... by Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar, Angela Dispenzieri, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Robert Z. Orlowski, Bart Barlogie

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

    Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma by Jatin J. Shah, Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, Suzanne Lentzsch, Dan T. Vogl, Christina L. Gomes, N G Pascucci, David Smith, Robert Z. Orlowski, Brian G.M. Durie

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

    Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone... by Lia A. Moulopoulos, Vassilis Koutoulidis, Jens Hillengaß, Elena Zamagni, Jesús Dámaso Aquerreta, Charles Roche, Suzanne Lentzsch, Philippe Moreau, Michèle Cavo, Jesús F. San Miguel, Meletios Α. Dimopoulos, S. Vincent Rajkumar, Brian G.M. Durie, Evangelos Terpos, Stefan Delorme

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

    Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma by David C. Johnson, Sophie L. Corthals, Brian A. Walker, Fiona M. Ross, Walter M. Gregory, Nicholas J. Dickens, Henk M. Lokhorst, Hartmut Goldschmidt, Faith E. Davies, Brian G.M. Durie, Brian Van Ness, J. A. Child, Pieter Sonneveld, Gareth J. Morgan

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

    Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321 by Bart Barlogie, Robert A. Kyle, Kenneth C. Anderson, Philip R. Greipp, Hillard M. Lazarus, David D. Hurd, Jason McCoy, Dennis F. Moore, Shaker R. Dakhil, Keith S. Lanier, Robert Chapman, Jeana Cromer, Sydney E. Salmon, Brian G.M. Durie, John C. Crowley

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: